Oncotelic Therapeutics (OTCQB: OTLC) has launched an AI-powered manufacturing services platform designed to address a critical bottleneck in the biotechnology industry: access to full Good Manufacturing Practice (GMP) infrastructure. The platform integrates Oncotelic's proprietary PDAOAI™ architecture with digital manufacturing technologies and intelligent robotics developed in collaboration with TechForce Robotics, the company's strategic robotics and automation partner. According to a recent article highlighting the launch, the initiative aims to bring artificial intelligence not just into drug discovery but into the manufacturing workflows that determine whether a therapy moves efficiently from development toward commercialization.
The platform is already deployed at Oncotelic's GMP-certified SAPU manufacturing facility, where it supports the company's own clinical pipeline. This adds a second dimension to Oncotelic's story: while it remains a clinical-stage biotech, the AI-GMP platform could extend its role into enabling infrastructure for other drug developers. If adopted commercially, the platform creates a services-based revenue opportunity while simultaneously strengthening Oncotelic's internal development engine. Combined with TechForce Robotics' automation capabilities, the launch reflects a broader industry shift toward intelligent manufacturing systems that reduce manual workload and tighten compliance discipline.
Oncotelic Therapeutics is a clinical-stage biopharmaceutical company focused on oncology and immunotherapy products, targeting high-unmet-need cancers and rare pediatric indications with innovative, late-stage therapeutic candidates. The company benefits from the robust portfolio of inventions created by its CEO, Dr. Vuong Trieu, who has filed more than 150 patent applications and holds 39 issued U.S. patents. Beyond its internal programs, Oncotelic also licenses and codevelops select drug candidates through joint ventures. Currently, the company owns 45% of GMP Bio, a joint venture under Trieu's leadership that is advancing its own pipeline of drug candidates, further complementing Oncotelic's strategic position in oncology and rare disease therapeutics.
For more information, visit the company’s newsroom at https://ibn.fm/OTLC. The full article discussing the platform launch can be viewed at https://ibn.fm/zB53J.
